Biogen Announces Webcast of Presentation at MassOpps 4th Annual Investor Conference.Business Editors MassOpps 4th Annual Investor Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2002 Biogen, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BGEN BGen abbr. brigadier general ) announced today that its presentation at the MassOpps 4th Annual Investor Conference will be webcast live on October 28, 2002. The live webcast begins at 10:10 a.m. (eastern) and can be accessed through Biogen's homepage, www.Biogen.com. About Biogen Biogen, Inc., winner of the U.S. National Medal of Technology, is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from worldwide sales of AVONEX(R) (interferon beta-1a interferon beta-1a Avonex, Rebif Pharmacologic class: Biological response modifier Therapeutic class: Antiviral, immunoregulator Pregnancy risk category C Action) for treatment of relapsing forms of multiple sclerosis, (Please see full prescribing information at http://www.avonex.com.), and from the worldwide sales by licensees of a number of products. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases Autoimmune diseasesA group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , neurological diseases, cancer, fibrosis and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. . The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen's homepage on the World Wide Web at www.Biogen.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion